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Abstract: 
Objectives: We measure and compare national continuum of HIV care estimates in Europe and 
Central Asia by three key sub-populations: men who have sex with men (MSM), people who inject 
drugs (PWID) and migrants.  
Methods: Responses to a 2016 ECDC survey of 55 European and Central Asian countries were used 
to describe continuums of HIV care for the sub-populations. Data were analysed using three 
frameworks: UNAIDS 90-90-90 targets; breakpoint analysis identifying reductions between adjacent 
continuum stages; quadrant analysis categorising countries using 90% cut-offs for continuum stages.  
Results: Overall, 29/48 countries reported national data for all HIV continuum stages (number: living 
with HIV; diagnosed; receiving treatment; virally suppressed). Six countries reported all stages for 
MSM, seven for PWID and two for migrants. Thirty-one countries did not report data for MSM (34 
for PWID and 41 for migrants). In countries that provided key-population data, overall, 63%, 40% 
and 41% of MSM, PWID and migrants living with HIV were virally suppressed respectively (compared 
to 68%, 65% and 68% nationally, for countries reporting key-population data). Variation was 
observed between countries, with higher outcomes in sub-populations in Western Europe compared 
to Eastern Europe and Central Asia.  
Conclusions: Few reporting countries can produce the continuum of HIV care for the three key 
populations. Despite limitations, differences exist in outcomes between the general and key 
populations. While MSM broadly mirror national outcomes (in the West), PWID and migrants 
experience poorer treatment and viral suppression. Countries must develop continuum measures 
for key populations to identify and address inequalities. 
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Introduction 
The continuum of HIV care has become one of the central metric through which the public health 
response to the HIV epidemic can be evaluated at the national level1. Its importance has been 
recognised by UNAIDS that established in 2014 the 90-90-90 targets with the aim that 90% of all 
those living with HIV are diagnosed, 90% of those diagnosed receive antiretroviral therapy and 90% 
of those receiving treatment achieve viral suppression by 20202. This is equivalent to an overall 73% 
viral suppression proportion among all people living with HIV. The concept has been integrated into 
WHO treatment guidelines3 and not only allows an assessment of the extent that all people living 
with HIV have reduced risk of mortality4,5,6 and untransmissible levels of virus7, but also identifies the 
stages along the continuum of care where further interventions are needed8. 
In 2014, an ECDC survey used to collect data as part of monitoring the implementation of the 2004 
Dublin Declaration9 produced valuable information on how, and the extent to which, European and 
Central Asian countries were monitoring the continuum of care for people living with HIV. At this 
time, only 16 European and Central Asian countries were able to report data on the complete 
continuum at the national level10. By 2017, national continuums of HIV care estimates had been 
published by 82 countries globally1.  
Standard presentations of the HIV continuum of care at the national level are likely to mask 
variations that exists in and between key sub-populations. National descriptions of the continuum of 
care stratified by key populations have been undertaken in the United States11,12,13,14,15,16, the United 
Kingdom (UK)17, Belgium18, Canada19,20 Denmark21, France22, Georgia23, Greece24, and Russia25 and 
through international comparison26. However, no baseline continuum of HIV care data is available 
for key populations for the whole European and Central Asian region. This information is needed to 
identify and reduce potential inequalities that exist between key populations both within and 
between countries. 
In view of this, the 2016 ECDC Dublin Declaration questionnaire asked countries to report data for 
their continuum of care10 estimates at national level and for key populations. We used data reported 
for a four stage continuum of care10 for three key populations: men who have sex with men (MSM), 
people who inject drugs (PWID) and migrants (i.e. people born outside of their country of diagnosis). 
We adopt a multi-framework approach10 to analyse continuums for each populations.  
Methods 
The 2016 Dublin Declaration monitoring questionnaire was distributed in electronic PDF format to 
nominated national representatives in 55 countries. Countries were asked to report available data 
for the countries’ entire population as a whole, including all persons living with HIV from key 
populations and other groups (hereafter referred to as “national data”) as well as data for three key 
populations (MSM, PWID, migrants) on the following  
continuum of care stages: 1) living with HIV infection; 2) diagnosed with HIV infection; 3) receiving 
anti-retroviral treatment; 4) virally suppressed1. Countries were also asked to provide their methods 
                                                            
1 
https://ecdc.europa.eu/sites/portal/files/media/en/healthtopics/aids/Documents/Dublin%20Declaration%20
Questionnaire%202016.pdf 
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for ascertaining the continuums for the key populations and to specify whether this varied from the 
national approach. Data validation consisted of raising data queries with country representatives 
directly and sharing draft analytical outputs for comment. 
We analysed the number of countries that reported: a) all four stages; b) no stages; c) and at least 
two consecutive stages of the continuum of care nationally and by key population. The methods that 
specific countries used to define and measure national continuum stages have been described 
previously10.  In analyses where data from multiple countries were combined, each element of the 
continuum was summed across countries and analyses undertaken using the summed totals. 
Three main analyses were conducted: analysis against the 90-90-90 targets, breakpoint analysis and 
quadrant analysis. In each instance, comparisons were made between key populations and the 
national data restricted only to those countries where relevant data were available.  
The 90-90-90 analysis monitors progress towards the targets described above. The breakpoint 
analysis27 identifies countries that had substantial reductions between any two successive stages 
along the continuum. Regardless of where it occurred in the continuum, a first breakpoint was set as 
a reduction of >10% between adjacent stages, in line with the 90- 90-90 targets, and a second 
breakpoint was set as a reduction of >25%. For the quadrant analysis10 cut-off points of 90% were 
used to divide countries into quadrants based on the observed data. Two quadrant analyses were 
undertaken. In the first, quadrants were defined by the percentage of people estimated to be living 
with HIV who had been diagnosed against the percentage of those diagnosed who were on 
treatment28. The second analysis plotted those diagnosed and treated against those treated and 
virally suppressed.  
Results  
Overall, 48 countries responded to the survey. Of these, 29 reported national data for all four stages 
of the continuum (Figure 1: Albania, Armenia, Austria, Azerbaijan, Belgium, Bulgaria, Croatia, 
Denmark, France, Georgia, Germany, Greece, Hungary, Italy, Kazakhstan, Kyrgyzstan, Luxembourg, 
Malta, Moldova, Montenegro, the Netherlands, Portugal, Romania, Serbia, Spain, Sweden, 
Switzerland, Tajikistan and the United Kingdom). All four stages were reported by six countries for 
MSM (Austria, Azerbaijan, France, Germany, Kyrgyzstan and the UK) and by seven countries for 
PWID (Austria, Azerbaijan, France, Germany, Kazakhstan, Kyrgyzstan and the UK). Only Austria and 
France were able to report all four stages of the continuum among their migrant populations.  
Only three countries were unable to report national data on any stage of the continuum, compared 
to 31 countries for MSM, 34 for PWID and 41 for migrants. Thirteen countries provided at least two 
consecutive stages for MSM populations, 14 for PWID and four for migrants. Among countries 
reporting national and key population continuums, all countries reported using the same approach 
to their measurement and construction of national and key population continuums of care, with the 
exception of the Ukraine, Germany and Kosovo. 
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Frameworks for analysing and interpreting continuum of care data 
90-90-90 
For the 29 countries reporting overall national data on all four stages, 81% of all people living with 
HIV were diagnosed, 68% were treated and 60% were virally suppressed. Among the six countries 
reporting MSM data, the equivalent figures were 83%, 70% and 63% (Figure 2). These figures were 
broadly in line with the national data when restricted to the same six countries that submitted MSM 
data (84%, 74% and 68%). Among the seven countries reporting PWID data, the proportion of PWID 
living with HIV who were diagnosed (82%) was similar to the national estimates (83%). However, the 
proportion of all PWID living with HIV who were treated and were virally suppressed was 
substantially lower compared to the national outcomes (57% and 40%, respectively for PWID 
compared to 71% and 65%, nationally). Among the two countries reporting migrant data, migrants 
had lower outcomes across all stages of the continuum compared to the national picture (73%, 51% 
and 41% respectively for migrants, compared to 84%, 75% and 68% nationally).  
Quadrant analysis 
Figures 3A, 3C and 3E present countries assigned to quadrants depending on the percentage of 
people estimated to be living with HIV who had been diagnosed plotted against the proportion 
diagnosed who had been treated. In these analyses, no countries reported any of the key 
populations to be in the highest quadrant (>90% for both measures). Figure 3A shows that while 
outcomes for MSM were relatively high for Austria, France, Germany, Italy and the UK (range 82%-
88% for those living with HIV who were diagnosed vs. range 76%- 90% for those diagnosed and 
treated), outcomes for Kyrgyzstan and the Ukraine were much lower (4% vs. 23% and 23% vs. 25% 
respectively).  Among PWID, outcomes were better for countries in Western Europe (range 77%-97% 
for those living with HIV who were diagnosed vs. range 81%-88% for those diagnosed and treated for 
Austria, Germany, Italy and the UK) compared to countries in Eastern Europe and Central Asia (range 
22%-85% vs. 21%-64% respectively for Azerbaijan, Kazakhstan, Kyrgyzstan, Ukraine and Tajikistan) 
(Figure 3c). 
Figures 3B, 3D and 3E present information on the proportion diagnosed and treated against the 
proportion treated who are virally suppressed. MSM were in the highest quadrant in the UK (90% vs. 
96%) with Germany almost meeting this benchmark (89% vs. 90%). Overall, Figure 3B shows some 
variation between countries (range 43%-90% vs. 51%-96%), with values lowest for Azerbaijan and 
Kyrgyzstan (54% vs. 51% and 43% vs. 70% respectively). Figure 3D shows more variation overall 
among PWID (range 21%-88% vs. 16%-93%) with Kazakhstan, Kyrgyzstan and Tajikistan below 50% 
on both metrics. In the UK, migrants were in the highest quadrant (91% vs. 95%) compared to 
Austria and France (Figure 3E, 83% vs. 65% and 70% vs. 81% respectively).  
Breakpoint analysis 
At the national level, 38 out of 40 countries had least one breakpoint (>10%) (Table 1): 86% (31/36) 
between the estimated number living with HIV and number diagnosed; 82% (32/39) between the 
number diagnosed and number treated; 72% (26/36) between those treated and those virally 
suppressed. Among countries reporting MSM continuum data, the equivalent percentage and 
number of countries reporting at least one breakpoint (>10%) was 100% (8/8), 92% (11/12) and 80% 
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(8/10). For PWID, 70% (7/10), 100% (13/13) and 89% (8/9) of countries reported at least one 
breakpoint (>10%), respectively. The equivalent figures for countries reporting continuum data for 
migrants were 100% (3/3), 75% (3/4) and 67% (2/3).  
Overall, 25% (2/8) countries reporting MSM data had a breakpoint greater than 25% between those 
living with HIV and those diagnosed. Equivalent figures were 50% both for those diagnosed and 
treated and those treated and virally suppressed (6/12 and 5/10 respectively). Among countries 
reporting PWID data, 40% (4/10) reported breakpoints of at least 25% between those living with HIV 
and diagnosed. Equivalent figures were 69% (9/13) and 56% (5/9) among those diagnosed and 
treated and those treated and virally suppressed respectively. 
Discussion 
To our knowledge this is the first time estimates of the continuum of HIV care for key populations in 
Europe and Central Asia were calculated. These results can be used as a baseline against which to 
monitor progress towards implementation of continuums of care for key populations, and to inform 
public health measures to improve HIV outcomes for these populations. At present, only six, seven 
and two of the 48 reporting countries are able to provide complete continuum data for MSM, PWID 
and migrant populations, respectively. The paucity of data is concerning and needs to improve. The 
little information is available from these countries indicates substantial inequalities in estimates for 
key populations compared to overall national data for the entire population of people living with 
HIV. While outcomes for MSM populations broadly reflect the national picture (63% viral 
suppression in MSM vs. 68% nationally), PWID and migrants show poorer outcomes in all stages of 
the continuum with a viral suppression rate of around 40% compared to around 65% nationally.  
The variation in continuum outcomes between key populations broadly reflects the geographic 
diversity of the populations affected by HIV in the region and the history of the epidemics in each 
country, with older epidemics in the West, and newer in the East.; due to effective treatment, 
countries with older epidemics will consistently have relatively high numbers of people living with 
diagnosed HIV infection. Compared to the other countries in the region, a higher proportion of 
people newly diagnosed in countries in Western Europe probably acquired their HIV infection 
through sex between men29. In this setting, HIV continuum outcomes are generally higher and better 
outcomes among MSM largely reflect this30,31,32. However, the quadrant and breakpoint analysis 
suggests that outcomes among MSM are poorer in Eastern European and Central Asian countries 
compare to the national picture in this setting, particularly in relation to the proportion diagnosed 
and proportion receiving treatment, which could be explained by the challenging legal and cultural 
context for gay, bisexual and transgender communities in some of these countries33.  
While the estimates are only slightly below the national picture in Western European countries, 
PWID in countries in Eastern Europe and Central Asia have consistently worse estimates compared 
to the national picture in all analytical frameworks. In these countries, HIV epidemics are more likely 
to be concentrated among PWID29, a population that is consistently shown to experience poorer 
outcomes in relation to treatment and viral suppression39,40. In general, PWID are less likely to be 
retained in care34,35 less likely to start antiretroviral treatment36,37 more likely to interrupt 
treatment38 and less likely to achieve suppressed viral load39,40 compared to the national picture. 
Within PWID populations, better outcomes have been identified where PWID report lower levels of 
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drug and alcohol use41 and availability of and engagement with effective drug treatment 
programmes42,43.  
In our analysis, continuum data are only available for migrants from Austria, France, Italy and the UK. 
These are all settings where outcomes along the continuum are higher than average in Europe, so 
outcomes for migrants in these countries may not reflect the overall situation in Europe and Central 
Asia. However, in all four countries, this population achieves sub-optimal outcomes compared to the 
national picture. Monitoring the HIV continuum of care in relation to migrant populations is 
particularly challenging due to lack of information44 (especially for undocumented migrants, who are 
the most vulnerable group and least likely to be in HIV care, receive treatment and attain viral 
suppression45,46) and to high levels of mobility. The absence of data is of concern because migrants 
account for a significant proportion of new HIV diagnoses in Europe, are most likely to be diagnosed 
late47,29 and to die sooner48, and may be less likely to seek health care due to concerns about 
migration status49.  
We aimed to assess the data availability and quality for different metrics to monitor the continuum 
of care between different populations; an evaluation of the public health utility of each of the 
metrics is not the focus of this work. However, we reiterate the need to develop further 
epidemiological rigour and a consensus in approach to monitor the continuum of care. Much of this 
work should focus on estimating the size of the undiagnosed population and ensuring this 
information is presented alongside the 90:90:90 targets to aid interpretation (for instance, a country 
with a 90% of the population diagnosed may have a large undiagnosed population that drives 
transmission)50. This work aimed to assess the data availability and quality.  Since we identified 
limited data availability and quality, this together with the differences between countries in the 
methods used to estimate and collect national data10, means that the baseline measurements 
should be interpreted with caution. With few exceptions, countries reportedly used the same 
approach to data collection in the construction of national and key population continuums and, as 
such, the same limitations are relevant and significant in the interpretation of our results10 and we 
reiterate the need to work towards a consensus in approach to monitor the continuum of care.  
Furthermore, since the relative size and characteristics of each key sub-population within each 
country’s epidemic varies considerably, overall national data for all PLHIV are not likely to represent 
the nuanced and diverse situation for the whole of Europe and Central Asia. It is also important to 
note that the countries that were able to monitor the continuum of care in key populations were 
also likely to be the countries with better HIV outcomes overall. Consequently, the data presented 
probably overestimates the outcomes experienced by key populations in the region as a whole 
To maximise the use of available data on the HIV care continuum we adopted a multi-framework 
approach. These analyses help to identify the specific stages of the continuum of care where further 
investment is required. Losses along any stage of the continuum of care are not only of clinical 
concern for individual patients but also have public health implications in relation to onward 
transmission of HIV.  
In Europe, HIV continues to be an infection that disproportionately affects key populations who face 
discrimination and stigmatisation in many settings. Our results indicate that there is a need to 
improve availability and uptake of HIV testing, linkage to effective ART, and adherence support to 
achieve viral suppression generally in Europe and Central Asia, and for PWID and migrant 
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populations in particular. It is critical that countries invest in the development and use of more 
robust methods to monitor the HIV continuum of care for key populations in order to identify and 
tackle inequalities in HIV care and public health outcomes experienced by these populations. 
  
 
‘* National comparisons provided only for countries that provided the key population data. 
Countries included: MSM: Austria, Azerbaijan, France, Germany, Kyrgyzstan and the UK; PWID: 
Austria, Azerbaijan, France, Germany, Kazakhstan, Kyrgyzstan and the UK; migrants: Austria and 
France 
0
10
20
30
40
50
No data Number
living with
HIV
Number
diagnosed
Number
receiving
treatment
Number
virally
suppressed
All four
stages
Figure 1: Number of European and Central Asian 
countries reporting data for different stages of the HIV 
continuum of care, reported in 2016 (n = 48). 
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Figure 2: Comparison of the continuum of HIV care for key populations 
against national continuums, reported in 2016* 
Key population National population
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Figure 3: Quadrant analysis: proportion of persons living with diagnosed HIV vs those diagnosed 
receiving treatment (A,C,E) and the proportion diagnosed treated vs those treated and virally 
suppressed (B,D,F), by key population and country, reported in 2016 
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Table 4: Breakpoints in the HIV continuum of care, by key population, reported in 2016 
 
Key: red indicates a stage that is <75% of its predecessor; amber indicates a stage that is 75-89% of 
its predecessor; green indicates a stage that is >90% of its predecessor. Red and amber correspond 
to Raymond’s concept of breakpoints27. Grey indicates no data reported.  
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Albania 50% 65% 32%
Armenia 48% 55% 68%
Austria 88% 85% 76% 88% 85% 76% 96% 81% 75% 73% 83% 65%
Azerbaijan* 53% 63% 52% 54% 51% 57% 64% 24%
Belgium 84% 84% 95% 86%
Bulgaria 64% 36% 87%
Croatia 65% 87% 88%
Czech Republic 71% 85% 71% 89% 63%
Denmark 91% 94% 94%
Estonia 84% 40% 0%
France* 84% 89% 91% 83% 76% 87% 96% 83% 85% 73% 70% 81%
Georgia 45% 70% 78% 77% 70% 65% 74%
Germany 85% 84% 93% 82% 89% 90% 89% 82% 78%
Greece 78% 67% 73%
Hungary 87% 53% 93%
Israel 74% 69%
Italy 88% 88% 87% 83% 69% 97% 68% 84% 70%
Kazakhstan 77% 35% 57% 67% 47% 22%
Kosovo 30%
Kyrgyzstan 65% 48% 41% 4% 43% 70% 85% 23% 46%
Latvia 27% 0%
Lithuania 70% 30% 0%
Luxembourg 87% 75% 91%
Malta 75% 96% 86%
Moldova 57% 38% 69%
Montenegro 76% 67% 69% 67% 74% 33%
Netherlands 88% 87% 92%
Poland 57% 63% 32%
Portugal 70% 67% 78%
Romania 98% 77% 51%
Serbia 63% 66% 95%
Slovakia* 79%
Slovenia 91% 83%
Spain 82% 92% 88%
Sweden 90% 95% 95%
Switzerland 82% 91% 97%
Tajikistan* 49% 56% 21% 54% 71% 21% 16%
Ukraine 57% 48% 0% 23% 25% 44% 59%
United Kingdom 87% 96% 94% 85% 90% 96% 77% 88% 93% 91% 95%
Uzbekistan 90% 40% 0%
77% 76% 87% 54% 80% 91% 65% 61% 57% 77% 81% 91%
Total MSM PWID Foreign born mirgrants
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